ASX:ACL

Australian Clinical Labs Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive ACL News and Ratings via Email

Sign-up to receive the latest news and ratings for Australian Clinical Labs and its competitors with MarketBeat's FREE daily newsletter.

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology services. The company offers all routine pathology tests, advanced pathology, first trimester screening and non-invasive prenatal testing, chemical pathologand, haematology, histopathology, immunology, serology and microbiology, functional pathology, and commercial drug and alcohol testing services. It also offers COVID-19, testing guide, GP services, and specialists services. The company offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 1987 and is based in Clayton, Australia. Clinical Laboratories Pty Ltd operates as a subsidiary of Healthscope Group.

Brokers using the lockdown to upgrade earnings forecasts on these ASX 200 shares
July 18, 2021 | msn.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolASX:ACL
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.clinicallabs.com.au
Phone61 3 9538 6777
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$519.50 million
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Australian Clinical Labs.

0.0 Community Rank

Outperform Votes
Australian Clinical Labs has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Australian Clinical Labs has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Australian Clinical Labs and other stocks. Vote “Outperform” if you believe ACL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Australian Clinical Labs does not currently pay a dividend.
Dividend Growth
Australian Clinical Labs does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Australian Clinical Labs insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Australian Clinical Labs (ASX:ACL) Frequently Asked Questions

What stocks does MarketBeat like better than Australian Clinical Labs?

Wall Street analysts have given Australian Clinical Labs a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Australian Clinical Labs wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Australian Clinical Labs' key executives?

Australian Clinical Labs' management team includes the following people:

Ms. Melinda McGrath, CEO & Exec. Director
Mr. James Davison, Chief Financial Officer
Mr. Anthony Friedli, Chief Operating Officer
Mr. Sean Jackson, Chief Information Officer
Mr. Joe Geran, National Marketing Director
Associate Prof. Tony Landgren, National Medical Director & Chief Pathologist
Mr. Chris Brownlow, Chief Exec. Officer of New South Wales & Australian Capital Territory
Ms. Shae Seymour, Chief Exec. Officer of Western Australia
Mr. Eric Swayn, Chief Exec. Officer of South Australia & Northern Territory

Who are some of Australian Clinical Labs' key competitors?

Some companies that are related to Australian Clinical Labs include (BUX) (BUX), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), dorsaVi (DVL), Epigenomics (EPGNY), Eternity Healthcare (ETAH), Genetic Signatures (GSS), Genetic Technologies (GTG), Imagin Medical (IME), Imagion Biosystems (IBX), Integral Diagnostics (IDX), Lifespot Health (LSH), Med BioGene (MBGNF) and Medical Imaging (MEDD).
View all of ACL's competitors.

What is Australian Clinical Labs' stock symbol?

Australian Clinical Labs trades on the ASX under the ticker symbol "ACL."

How much money does Australian Clinical Labs make?

Australian Clinical Labs has a market capitalization of $0.00 and generates $519.50 million in revenue each year.

How many employees does Australian Clinical Labs have?

Australian Clinical Labs employs 2,716 workers across the globe.

What is Australian Clinical Labs' official website?

The official website for Australian Clinical Labs is www.clinicallabs.com.au.

How can I contact Australian Clinical Labs?

The company can be reached via phone at 61 3 9538 6777.

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.